BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1532 related articles for article (PubMed ID: 28058965)

  • 1. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
    Carnero Contentti E; Daccach Marques V; Soto de Castillo I; Tkachuk V; Ariel B; Castillo MC; Cristiano E; Diégues Serva GB; Dos Santos AC; Finkelsteyn AM; López PA; Patrucco L; Molina O; Pettinicchi JP; Toneguzzo V; Caride A; Rojas JI
    J Neurol; 2020 May; 267(5):1260-1268. PubMed ID: 31932911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder.
    Hu Y; Sun Q; Yi F; Yao L; Tian Y; Tang H; Luo M; Xie N; Wang Z; Liao X; Zhou L; Xu H; Zhou Y
    Front Immunol; 2022; 13():1056944. PubMed ID: 36569880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
    Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients.
    Carnero Contentti E; Daccach Marques V; Soto de Castillo I; Tkachuk V; Antunes Barreira A; Armas E; Chiganer E; de Aquino Cruz C; Di Pace JL; Hryb JP; Lavigne Moreira C; Lessa C; Molina O; Perassolo M; Soto A; Caride A
    Mult Scler Relat Disord; 2018 Jan; 19():73-78. PubMed ID: 29156226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders.
    Zhang LJ; Yang LN; Li T; Wang J; Qi Y; Zhang DQ; Yang CS; Yang L
    Int J Neurosci; 2017 Apr; 127(4):334-338. PubMed ID: 27788616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very late onset neuromyelitis optica spectrum disorders.
    Nakahara K; Nakane S; Nagaishi A; Narita T; Matsuo H; Ando Y
    Eur J Neurol; 2021 Aug; 28(8):2574-2581. PubMed ID: 33960076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus.
    Sepulveda M; Delgado-García G; Blanco Y; Sola-Valls N; Martinez-Lapiscina EH; Armangué T; Montejo C; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Escudero D; Ruiz-García R; Llufriu S; Dalmau J; Graus F; Saiz A
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31471461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    Huh SY; Min JH; Kim W; Kim SH; Kim HJ; Kim BJ; Kim BJ; Lee KH
    Mult Scler; 2014 May; 20(6):695-704. PubMed ID: 24072726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low T3 syndrome in neuromyelitis optica spectrum disorder: Associations with disease activity and disability.
    Cho EB; Min JH; Cho HJ; Seok JM; Lee HL; Shin HY; Lee KH; Kim BJ
    J Neurol Sci; 2016 Nov; 370():214-218. PubMed ID: 27772762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders.
    Wang X; Yi H; Liu J; Li M; Mao ZF; Xu L; Peng FH
    J Neurol Sci; 2016 Jul; 366():3-7. PubMed ID: 27288767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
    Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
    Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.